Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 4/20 | 0.63 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16543002 | 0.88 | METAP1 (0.61) | METAP1F2ALDH1A1NPC1NFE2L2 | |
| SCHEMBL14712992 | 0.82 | METAP1 (0.63) | METAP1F2ALDH1A1RAB9ASIRT2 | |
| SCHEMBL14713060 | 0.79 | METAP1 (0.60) | METAP1F2ALDH1A1RAB9ASIRT2 | |
| SCHEMBL14712996 | 0.78 | METAP1 (0.59) | METAP1F2ALDH1A1RAB9ASIRT2 | |
| SCHEMBL13848519 | 0.78 | METAP1 (1.00) | METAP1F2ALDH1A1RAB9ASIRT2 | |
| SCHEMBL4044276 | 0.78 | METAP1 (1.00) | METAP1F2ALDH1A1RAB9ASIRT2 | |
| SCHEMBL14713051 | 0.77 | KMT2A (0.47) | METAP1ALDH1A1NPC1NFE2L2MAPT | |
| SCHEMBL14712988 | 0.75 | METAP1 (0.71) | METAP1F2ALDH1A1RAB9ASIRT2 | |
| SCHEMBL16543004 | 0.74 | KMT2A (0.50) | ALDH1A1NPC1NFE2L2MAPTKMT2A | |
| SCHEMBL14712879 | 0.74 | KMT2A (0.50) | ALDH1A1NPC1NFE2L2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994554-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994554-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2018-05-17 | — | — | US | disclosed |
| US-9878998-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878998-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| WO-2013024447-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAX | METAP1 2044/4885F2 4684/4885ALDH1A1 186/4885 |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAK1 | METAP1 2416/4885F2 4611/4885ALDH1A1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.